Cue Biopharma Q2 GAAP EPS misses, revenue beats

Seeking Alpha··Read original
2▲0 ▼1Impact / 5
Summary · why it matters

Cue Biopharma reported second-quarter 2026 financial results with a GAAP EPS of negative $24.14, missing estimates by $22.23. Revenue came in at $7.88 million, up 167.1% year-over-year, beating expectations by $5.78 million. As of June 30, 2026, the company had $17.4 million in cash and cash equivalents after incurring one-time cash outflows related to the license agreement.

Impact on assets 1

Biotech & Genomic Medicine▼ · 1 stocks
Cue Biopharma
CUE
▼ NegativeCapitalrelevance

GAAP EPS of -$24.14 missed estimates by $22.23, indicating worse-than-expected losses.

© 2026 MarketIVNews